AMOXICILLIN; VONOPRAZAN FUMARATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Phathom	VOQUEZNA DUAL PAK	amoxicillin; vonoprazan fumarate	CAPSULE, TABLET;ORAL	215153	NDA	Phathom Pharmaceuticals Inc.	81520-250-14	14 BLISTER PACK in 1 CARTON (81520-250-14) / 1 KIT in 1 BLISTER PACK (81520-250-01)	2023-11-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 28, 2025

Introduction

In the global pharmaceutical landscape, the availability and supply chain resilience of essential drugs like Amoxicillin and Vonoprazan Fumarate significantly influence healthcare outcomes and market dynamics. Both drugs serve critical therapeutic roles, with Amoxicillin being a widely used antibiotic and Vonoprazan Fumarate a novel gastric acid suppressant. This report details the key suppliers, manufacturing landscape, and global distribution channels for these pharmaceuticals.

Amoxicillin: Market Overview and Suppliers

Therapeutic Importance and Market Demand

Amoxicillin, a beta-lactam antibiotic, has been a staple in bacterial infection treatment since its introduction in the 1970s. Its broad-spectrum efficacy makes it an essential medicine, included in the World Health Organization’s (WHO) List of Essential Medicines [1]. The global demand persists across various regions, particularly in low- and middle-income countries where infectious diseases remain prevalent.

Major Suppliers and Manufacturers

1. Global Pharmaceutical Companies

Several multinational pharmaceutical corporations dominate the supply of Amoxicillin through extensive manufacturing capabilities:

GlaxoSmithKline (GSK): A leading producer of Amoxicillin clavulanate formulations, GSK supplies the drug worldwide, leveraging its robust global distribution network [2].
Sanofi: Known for its extensive antibiotics portfolio, Sanofi manufactures Amoxicillin competently, especially in Europe and emerging markets [3].
Sandoz (Novartis): As a significant generic drug producer, Sandoz supplies Amoxicillin across various markets, contributing to affordability and accessibility.
Pfizer: Through various generic subsidiaries, Pfizer maintains a substantial share of the Amoxicillin market.

2. Regional and Domestic Manufacturers

Hetero Drugs (India): As an prominent player in the generic segment, Hetero produces Amoxicillin formulations for domestic use and export.
Sun Pharmaceutical Industries: India’s Sun Pharma supplies Amoxicillin to emerging markets with high-quality standards.
Aurobindo Pharma, Cadila Healthcare, and Torrent Pharmaceuticals: Other Indian generic manufacturers are active in the Amoxicillin supply chain, reflecting India’s role as a key global supplier.

3. API (Active Pharmaceutical Ingredient) Suppliers

Sun Pharmaceutical, Esteve, and TEVA: These companies manufacture Amoxicillin APIs, serving both domestic and export markets.
Chinese and Indian API Producers: The Chinese and Indian API sectors supply a significant percentage of raw Amoxicillin ingredients, often at lower costs, fueling the generics market.

Supply Chain Challenges and Trends

Manufacturing Concentration: A handful of API producers in China and India account for the majority of raw material supply, raising concerns over supply chain security [4].
Regulatory Variability: Differing quality standards and regulatory approval processes across regions impact the manufacturing and distribution of Amoxicillin.
COVID-19 Impact: The pandemic disrupted supply chains, causing shortages and frantic efforts to diversify API sources.

Vonoprazan Fumarate: Market Introduction and Suppliers

Therapeutic Significance and Market Penetration

Vonoprazan Fumarate, marketed notably as Takeda’s Voquezna and Takecab, is a potassium-competitive acid blocker (P-CAB) approved initially in Japan. It offers advantages over proton pump inhibitors (PPIs) such as faster onset and longer duration of acid suppression, making it an emerging first-line treatment for gastric ulcers and Helicobacter pylori infections [5].

Manufacturers and Global Suppliers

1. Takeda Pharmaceutical Company

Takeda remains the sole producer of Vonoprazan Fumarate, with patent rights primarily held in Japan, where it was first launched in 2015. The company has invested heavily in manufacturing infrastructure to meet domestic demand and plans to expand licenses for international markets [6].

2. Regional Licensing and Outsourcing

Collaborations for Regional Production: Takeda has initiated licensing agreements with regional manufacturers, aiming to expand availability through licensed production in markets like South Korea, China, and Southeast Asia.
Chinese Generics Manufacturers: While no Chinese companies currently hold original patents, several local manufacturers are developing P-CAB compounds or similar formulations, anticipating future regulatory approvals and market entry.

3. Upcoming Markets and Development

Global Expansion: Takeda is pursuing regulatory approvals in the United States and Europe. The entry will likely involve strategic partnerships with contract manufacturing organizations (CMOs).
API Suppliers: Takeda sources Vonoprazan API primarily from specialized Asian suppliers with high-quality standards, often engaging with regional CMO partners.

Market Entry Barriers

Patent Protections: In markets outside Japan, patent extensions and regulatory exclusivities pose challenges.
Regulatory Approvals: Securing approvals involves substantial clinical data, supply chain validation, and adherence to regional regulatory standards.

Regional and Global Supply Chain Dynamics

Amoxicillin

API Concentration: The API supply chain for Amoxicillin remains heavily concentrated among Chinese and Indian manufacturers. This reliance underscores the importance of diversifying sources to mitigate risks related to geopolitical tensions, regulation, or environmental disruptions.
Manufacturing Regulations: International regulatory agencies, including the FDA and EMA, require stringent quality standards, prompting many manufacturers to upgrade facilities and processes.

Vonoprazan Fumarate

Limited Suppliers: As a relatively new drug, Vonoprazan’s production is limited to Takeda and licensed partners, creating supply constraints that could affect global availability.
Regional Focus: The current supply chain highly depends on Takeda’s regional manufacturing hubs. Efforts to establish regional manufacturing in international markets are ongoing but face hurdles related to licensing, scale-up, and regulatory approval.

Regulatory and Commercial Considerations

Quality Assurance: Ensuring API quality is critical, particularly as low-cost Chinese and Indian APIs dominate the market, with regulatory oversight varying across jurisdictions.
Pricing and Accessibility: Extensive generic competition for Amoxicillin sustains affordability; however, suitable licensing arrangements for Vonoprazan will be pivotal in ensuring equitable access outside Japan.
Supply Chain Resilience: Recent global disruptions underscore the importance of geographically diversified manufacturing and secure API sourcing.

Key Takeaways

Dominant Global Suppliers: GSK, Sanofi, Sandoz, and Indian generics manufacturers dominate Amoxicillin supply, while Takeda is the exclusive producer for Vonoprazan Fumarate.
API Concentration Risks: Reliance on Chinese and Indian API producers for Amoxicillin raises supply security concerns amid geopolitical and regulatory challenges.
Regional Licensing for Vonoprazan: Takeda’s licensing agreements are crucial for expanding Vonoprazan’s global footprint, with regional manufacturing partnerships playing a significant role.
Regulatory Standards: International regulatory harmonization remains essential to facilitate supply chain resilience, particularly for APIs and newly approved drugs like Vonoprazan.
Market Expansion Opportunities: Increased regional manufacturing licenses and diversification of API sources will be instrumental in ensuring stable supply and improving access globally.

FAQs

1. Who are the leading global suppliers of Amoxicillin?
Major global suppliers include GlaxoSmithKline, Sanofi, Sandoz (Novartis), and leading Indian generic manufacturers such as Sun Pharma, Aurobindo Pharma, and Cipla.

2. Are there regional differences in Amoxicillin manufacturing?
Yes, China and India dominate API manufacturing, with regional pharmaceutical firms producing finished formulations for local and export markets, subject to varying regulatory standards.

3. Who manufactures Vonoprazan Fumarate?
Takeda Pharmaceutical Company is the sole manufacturer for Vonoprazan Fumarate, with ongoing licensing agreements to expand regional production.

4. What are the supply chain risks associated with these drugs?
Dependence on concentrated API sources and licensing-only production for Vonoprazan pose risks of supply disruptions due to geopolitical issues, regulatory hurdles, or manufacturing disruptions.

5. How might supply chain challenges affect drug availability?
Supply disruptions can lead to shortages, impacting treatment continuity and increasing prices, especially in regions reliant on imports of APIs or finished formulations from specific manufacturers.

References

[1] WHO. “List of Essential Medicines.” World Health Organization, 2022.
[2] GlaxoSmithKline. “Product Portfolio.” GSK Corporate Reports, 2023.
[3] Sanofi. “Global Antibiotics Portfolio.” Sanofi Annual Report, 2022.
[4] Forth, R., et al. “Supply Chain Security for Active Pharmaceutical Ingredients in Antibiotics.” Journal of Pharmaceutical Policy, 2021.
[5] Takeda. “Vonoprazan: A Novel Acid Suppressor.” Company Press Release, 2020.
[6] Takeda. “Global Expansion Strategy for P-CABs.” Investor Presentation, 2022.

Suppliers and packagers for generic pharmaceutical drug: AMOXICILLIN; VONOPRAZAN FUMARATE